Advances in the Multi-omics Landscape of Follicular Lymphoma

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2023 Apr 17

PMID 37063433

Authors

Tianyuan Xu

Zhong Zheng

Weili Zhao

Affiliations

Soon will be listed here.

Abstract

Follicular lymphoma (FL) is the most common indolent lymphoma originating from germinal center B cells. FL represents a clinically and biologically heterogeneous disease. Most patients have favorable outcomes, but a subset of patients experiences early progression or transformation and has a poor prognosis. Abnormalities in FL cells and tumor microenvironment have been revealed using multi-omics techniques, including genomic, epigenomic, transcriptomic and proteomic analysis. Recurrent somatic gene aberrations mainly involve epigenetic modifiers, transcription factors, oncogenic pathways and microenvironment modulators. Single-cell transcriptomic analysis show marked inter- and intra-patient FL subclone heterogeneity. In addition, a comprehensive profile of microenvironmental components is provided, unveiling the crosstalk between tumor and microenvironment that induce FL progression and facilitate immune escape. Together, these studies provide insights into the mechanisms and biomarkers of high-risk FL populations, as well as the potential targeted and immunotherapy options. Future research should focus on integrating multi-omics aberrations to optimize therapeutic strategies in FL.

Citing Articles

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.

Zheng Z, Wang J, Sun R, Wang N, Weng X, Xu T Signal Transduct Target Ther. 2025; 10(1):29.

PMID: 39828715 PMC: 11743790. DOI: 10.1038/s41392-024-02105-7.

Identification and Functional Investigation of Hub Genes Associated with Follicular Lymphoma.

Zhu Y, Jin X, Liu J, Yang W Biochem Genet. 2024; .

PMID: 38802691 DOI: 10.1007/s10528-024-10831-4.

References

Bararia D, Hildebrand J, Stolz S, Haebe S, Alig S, Trevisani C . Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell Rep. 2020; 31(5):107522. DOI: 10.1016/j.celrep.2020.107522. View

Abe Y, Sakata-Yanagimoto M, Fujisawa M, Miyoshi H, Suehara Y, Hattori K . A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. Nat Cell Biol. 2022; 24(4):565-578. PMC: 9033586. DOI: 10.1038/s41556-022-00866-3. View

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S . Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. J Clin Oncol. 2016; 34(22):2575-82. DOI: 10.1200/JCO.2015.65.7163. View

Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D . Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clin Cancer Res. 2021; 27(8):2301-2313. PMC: 8046715. DOI: 10.1158/1078-0432.CCR-20-3741. View

Ribrag V, Kim W, Bouabdallah R, Lim S, Coiffier B, Illes A . Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017; 102(5):903-909. PMC: 5477609. DOI: 10.3324/haematol.2016.154377. View

Smeltzer J, Jones J, Ziesmer S, Grote D, Xiu B, Ristow K . Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res. 2014; 20(11):2862-72. PMC: 4058762. DOI: 10.1158/1078-0432.CCR-13-2367. View

Krysiak K, Gomez F, White B, Matlock M, Miller C, Trani L . Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017; 129(4):473-483. PMC: 5270390. DOI: 10.1182/blood-2016-07-729954. View

Okosun J, Wolfson R, Wang J, Araf S, Wilkins L, Castellano B . Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2015; 48(2):183-8. PMC: 4731318. DOI: 10.1038/ng.3473. View

10.

Roberto M, Varano G, Vinas-Castells R, Holmes A, Kumar R, Pasqualucci L . Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Immunity. 2021; 54(8):1807-1824.e14. PMC: 8475267. DOI: 10.1016/j.immuni.2021.07.009. View

11.

Banta K, Xu X, Chitre A, Au-Yeung A, Takahashi C, OGorman W . Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 T cell responses. Immunity. 2022; 55(3):512-526.e9. PMC: 9287124. DOI: 10.1016/j.immuni.2022.02.005. View

12.

Holmes A, Corinaldesi C, Shen Q, Kumar R, Compagno N, Wang Z . Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. J Exp Med. 2020; 217(10). PMC: 7537389. DOI: 10.1084/jem.20200483. View

13.

Yang Z, Kim H, Villasboas J, Price-Troska T, Jalali S, Wu H . Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Rep. 2019; 26(8):2178-2193.e3. PMC: 6402596. DOI: 10.1016/j.celrep.2019.01.085. View

14.

Misiak J, Jean R, Rodriguez S, Deleurme L, Lamy T, Tarte K . Human Lymphoid Stromal Cells Contribute to Polarization of Follicular T Cells Into IL-4 Secreting Cells. Front Immunol. 2020; 11:559866. PMC: 7562812. DOI: 10.3389/fimmu.2020.559866. View

15.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger A, Szczepanowski M . Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16(9):1111-1122. DOI: 10.1016/S1470-2045(15)00169-2. View

16.

Yang Z, Kim H, Villasboas J, Chen Y, Price-Troska T, Jalali S . Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017; 8(37):61425-61439. PMC: 5617435. DOI: 10.18632/oncotarget.18251. View

17.

van der Horst H, de Jonge A, Hiemstra I, Gelderloos A, Berry D, Hijmering N . Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021; 11(2):38. PMC: 7892878. DOI: 10.1038/s41408-021-00430-6. View

18.

Mondello P, Tadros S, Teater M, Fontan L, Chang A, Jain N . Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020; 10(3):440-459. PMC: 7275250. DOI: 10.1158/2159-8290.CD-19-0116. View

19.

Myklebust J, Irish J, Brody J, Czerwinski D, Houot R, Kohrt H . High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013; 121(8):1367-76. PMC: 3578953. DOI: 10.1182/blood-2012-04-421826. View

20.

Epron G, Ame-Thomas P, Le Priol J, Pangault C, Dulong J, Lamy T . Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2011; 26(1):139-48. DOI: 10.1038/leu.2011.179. View